Commonly grown weeds are rich sources of pollen and are causing allergy to many people globally. Russian thistle (Salsola kali), belonging to the family of Amaranthaceae which is well known for its allergenic potential. Russian thistle or Saltwort (prickly) pollen came into the limelight as serious allergens due to the extensive desertification brought by the drastic climate change in the last few years. Russian thistle is prevalent in dry, arid and semi-arid regions, although it has naturalized to regions of North America, Africa, Australia, Europe, and Asia. The peak pollen counts are generally seen between August and September. The characteristic feature of Russian thistle is the formation of “tumbleweed” upon maturing. Russian thistle pollen accounts for as a major aeroallergen in some of the regions. About 70% and nearly 50% of patients with pollen allergic symptoms tested positive in Spain and UAE, respectively for Russian thistle. Being an aeroallergen, inhalation of the Russian thistle pollens leads to allergic rhinitis (AR), asthma, rhino-conjunctivitis.
Sal k 1, a pectinmethylesterase, is the most well-characterized and the most potent allergen marker of Russian thistle pollen and is present in more than 50% of individuals prone to it. Other minor allergens include Sal k 2, a protein kinase homolog, Sal k 4, a profilin, and Sal k 5, which shows high cross-reactivity to Chenopodium album. The first case of allergy to Russian thistle was reported in Arizona, which to date reports a significant number of S. kali pollen allergies. Some regions in Spain like Murcia, Aragón, Andalucía, Levante, and Zaragoza reported for major cases of Russian thistle pollen allergy.
It shows a high level of cross-reactivity with other members of the family Amaranthaceae and with other species like Olea, Kiwi fruit, Birch pollen, etc. Allergen immunotherapy with Russian thistle pollen extracts has proved to be an effective treatment option for allergic reactions caused by this pollen.